The clinical case archive is a structured, hierarchical evaluation of 130 publicly assembled breast cancer case narratives involving repurposed antiparasitic agents—specifically ivermectin, mebendazole, and fenbendazole. Rather than presenting these accounts as informal testimonials or claiming established efficacy, the archive serves as a standardized hypothesis-generating classification system to identify recurring clinical patterns, metastatic distributions, and treatment combinations.
1. Core Research Framework and Objective
The archive addresses a specific methodological question: What recurring clinical patterns and response phenotypes appear within these reported cases, and which are sufficiently documented to warrant prospective clinical trials?
To prevent treating temporal association as proof of causality, the archive codes cases across several objective dimensions:
Response Phenotypes (P1–P8): Classifies specific tumor responses, including primary breast tumor regression (P1), nodal clearance (P2), bone healing/sclerosis (P3), visceral regression (P4), central nervous system/brain response (P5), biomarker/ctDNA decline (P6), pathological complete response at surgery (P7), and clinical/symptomatic improvement (P8).
Evidence-Verification Hierarchy (E0–E5): Grades documentation quality, ranging from E0 (insufficient information/pure testimonial) and E1 (unverified symptoms), up through E3 (serial CT, PET/CT, or MRI scans), E4 (pathology/surgery plus imaging), to E5 (independent pathology, serial imaging, and molecular confirmation).
Attribution Hierarchy (A1–A5): Assesses whether an outcome can be credited primarily to the repurposed agent (A1), a combination with conventional treatments (A2), sequential therapy (A3), a multi-intervention integrative protocol (A4), or remains indeterminate (A5).
Preserving Missing Data: Cases lacking verified details are explicitly coded as “NR” (Not Reported) rather than fabricating clinical stages, subtypes, or timelines, preventing artificial precision.


